What medications are recommended for treating akathisia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Akathisia Medications

For antipsychotic-induced akathisia, first-line treatment should be beta-blockers (propranolol 10-30 mg two to three times daily), benzodiazepines (lorazepam 0.5-1.25 mg), or mirtazapine (15 mg), with beta-blockers and benzodiazepines showing the strongest evidence for efficacy. 1, 2

Treatment Algorithm

Step 1: Antipsychotic Dose Adjustment

  • Reduce the antipsychotic dose if clinically feasible without worsening psychotic symptoms 3, 4, 2
  • Discontinue antipsychotic polypharmacy if present 2
  • Consider switching to an antipsychotic with lower akathisia liability (quetiapine or olanzapine) 5, 2

Step 2: First-Line Pharmacological Treatment

If dose reduction is insufficient or not possible, choose from these evidence-based options:

Beta-blockers (Preferred):

  • Propranolol 10-30 mg two to three times daily 5, 2
  • Ranked highest in comparative efficacy (P-score 0.8186 after benzodiazepines) 1
  • Contraindicated in patients with asthma, heart block, or significant bradycardia

Benzodiazepines:

  • Lorazepam 0.5-1.25 mg (can be sublingual) 6, 2, 7
  • Clonazepam as alternative 2
  • Highest P-score ranking (0.8186) in network meta-analysis 1
  • Caution: respiratory depression, confusion, ataxia in elderly 6

Mirtazapine (NaSSA):

  • 15 mg daily 5, 2, 8
  • Particularly effective for treatment-resistant akathisia 8
  • Acts as 5HT2A antagonist 2, 9

Step 3: Alternative Agents

If first-line treatments fail or are contraindicated:

Anticholinergics:

  • Biperiden 2-4 mg/day 7
  • Trihexyphenidyl 5 mg orally 9, 7
  • Not consistently helpful for akathisia specifically 3, but may be tried

Other 5HT2A Antagonists:

  • Cyproheptadine 9
  • Mianserin 9

Step 4: Combination Therapy

  • If monotherapy inadequate, combine beta-blocker with benzodiazepine 2
  • Consider adding mirtazapine to existing regimen for refractory cases 8

Critical Clinical Considerations

Diagnostic Pitfalls:

  • Akathisia is frequently misinterpreted as psychotic agitation or anxiety, leading to inappropriate antipsychotic dose increases 3
  • Use validated assessment scales (Barnes Akathisia Rating Scale) before and during treatment 2, 8
  • Distinguish from other movement disorders: dystonia, parkinsonism, tardive dyskinesia 3

Risk Factors:

  • High-potency antipsychotics (haloperidol) carry higher risk 3, 10
  • High doses or antipsychotic polypharmacy 10
  • Bipolar depression, substance abuse comorbidity 10
  • Second-generation antipsychotics (risperidone, aripiprazole) can also cause akathisia, though less frequently than first-generation agents 11, 10

Treatment Duration:

  • Evidence for duration of adjuvant medication use is limited 2
  • Reassess need for antiparkinsonian agents after acute phase or if antipsychotic dose is lowered 3
  • Cautious prescribing warranted given evidence limitations 2

Evidence Quality Note

The 2024 network meta-analysis 1 provides the most recent high-quality evidence, demonstrating significant efficacy for benzodiazepines (SMD vs placebo), beta-blockers, and NaSSA (mirtazapine). The 2018 Canadian guideline 2 offers the most comprehensive systematic approach to treatment. Notably, anticholinergics showed no significant difference from placebo in the meta-analysis 1, despite their common use, while beta-blockers were previously found ineffective in one older study 7—this discrepancy highlights the importance of the most recent evidence.

Avoid benztropine or trihexyphenidyl specifically for akathisia as recommended in older guidelines 11, as they are not consistently effective for this particular extrapyramidal symptom 3.

References

Research

The Assessment and Treatment of Antipsychotic-Induced Akathisia.

Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2018

Research

[Drug-Induced Akathisia].

Brain and nerve = Shinkei kenkyu no shinpo, 2017

Research

Akathisia and second-generation antipsychotic drugs.

Current opinion in psychiatry, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.